Albert Nathalie L, Galldiks Norbert, Ellingson Benjamin M, van den Bent Martin J, Chang Susan M, Cicone Francesco, Koh Eng-Siew, Law Ian, Le Rhun Emilie, Mair Maximilian J, Werner Jan-Michael, Berghoff Anna S, Furtner Julia, Minniti Giuseppe, Scott Andrew M, Short Susan C, Ivanidze Jana, Johnson Derek R, Suchorska Bogdana, Tolboom Nelleke, Tonn Joerg-Christian, Verger Antoine, Galanis Eva, Brastianos Priscilla K, Wen Patrick Y, Weller Michael, Lin Nancy U, Preusser Matthias
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Department of Neurology, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
Nat Med. 2025 May;31(5):1424-1430. doi: 10.1038/s41591-025-03633-7. Epub 2025 May 8.
Novel diagnostic and therapeutic opportunities are needed to improve medical care and outcome of patients with brain metastases, a frequent and severe complication of several cancer types. Currently, magnetic resonance imaging (MRI) is the primary method used for detection, treatment planning and disease monitoring in patients with brain metastases, but this method has limitations. These limitations mean that MRI can inform on lesion size but cannot directly measure the activity or viability of tumor tissue. Positron emission tomography (PET) imaging, however, can visualize metabolically active tumor cells and is therefore increasingly incorporated into cancer care to assess tumor burden and response to treatment. Here, we define the PET Response Assessment in Neuro-Oncology (RANO) for brain metastasis (BM) 1.0 criteria for metabolic response assessment of brain metastases using amino acid PET. By introducing an innovative endpoint for next-generation clinical trials, the PET RANO BM 1.0 criteria aim to facilitate development of novel therapies for patients with brain metastases.
需要新的诊断和治疗方法来改善脑转移患者的医疗护理和治疗结果，脑转移是几种癌症类型常见且严重的并发症。目前，磁共振成像（MRI）是用于脑转移患者检测、治疗规划和疾病监测的主要方法，但该方法存在局限性。这些局限性意味着MRI可以告知病变大小，但无法直接测量肿瘤组织的活性或生存能力。然而，正电子发射断层扫描（PET）成像可以可视化代谢活跃的肿瘤细胞，因此越来越多地被纳入癌症治疗中，以评估肿瘤负荷和对治疗的反应。在这里，我们定义了用于使用氨基酸PET评估脑转移瘤（BM）代谢反应的神经肿瘤学PET反应评估（RANO）1.0标准。通过为下一代临床试验引入创新的终点指标，PET RANO BM 1.0标准旨在促进脑转移患者新疗法的开发。
